植物性天然产品调节星细胞功能:阿尔茨海默氏病治疗策略
Huayuan Wei1, Guangming Zhang1, Xu Yan1
1School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
Phytomedicine : international journal of phytotherapy and phytopharmacology
|September 27, 2025
概括
来自植物的天然产品通过向星细胞功能,对阿尔茨海默病 (AD) 治疗有希望. 这些化合物调节关键的病理过程,为AD管理提供潜在的新治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,治疗选择有限.
- 星球细胞在阿尔茨海默氏症的发病过程中发挥着至关重要的作用.
- 自然产品通过向各种病理途径,为AD提供潜在的治疗益处.
研究的目的:
- 系统地审查和评估植物性天然产品的药用益处.
- 评估它们在调节与AD相关的星细胞介导过程中的有效性.
- 提供对AD进展的新型治疗策略的见解.
主要方法:
- 在PubMed和Web of Science进行了全面的文献搜索.
- 关键词包括"天然产品"",活性化合物"",阿尔茨海默病"和"星球细胞".
- 专注于2013年至2024年间发表的研究,并进行系统的分类和分析.
主要成果:
- 植物衍生化合物 (黄类,类,多类,类) 针对天体细胞的形态和功能.
- 这些化合物调节神经炎症,氧化压力,粉样β (Aβ) 代谢,陶过,线粒体功能障碍和ER压力.
- 挑战包括化合物变异性,低生物可用性和输送限制,影响临床转化.
结论:
- 本综述阐明了星球细胞和阿尔茨海默病之间的联系,强调了天然产品的治疗潜力.
- 自然产品为开发新型AD治疗提供了有希望的途径.
- 需要进一步的研究来克服挑战,并推进AD管理的治疗策略.
更多相关视频
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.7K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.5K
相关概念视频
Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
